Shared on 07 Nov 25
AQST: Extended Patent Protection Will Drive Sustained Share Price Upside
Analysts have recently raised their price targets for Aquestive Therapeutics, with notable increases from $7 to $8 and from $9 to $12. They cite strengthened patent protection for Anaphylm and a smoother regulatory pathway as key drivers behind their more optimistic outlook.
Shared on 24 Oct 25
Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.
Shared on 09 Oct 25
Fair value Increased 5.83%The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.
Shared on 24 Apr 25
Fair value Decreased 4.44%AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 9.78%AnalystConsensusTarget made no meaningful changes to valuation assumptions.